Skip to main content
. 2015 Mar 10;7(4):438–449. doi: 10.15252/emmm.201404580

Figure 5. CY exhibited activity with CLL samples.

Figure 5

  1. Dose curve of CY, fludarabine, and bendamustine using fresh CLL samples. Data represent mean ± SD.
  2. CY preferentially killed CLL cells over healthy B cells. Data represent mean ± SD.
  3. Toxicity of CY190602 in patients harboring deletion of chromosome 17p (including p53 locus) compared to patients without del17p. Viability of samples was normalized to background apoptosis for individual patient samples. For all experiments, cell viability was determined after 72 h of drug treatment. Data represent mean ± SD.